Tagged with Mexico

Mexico Alberto Wicker, CEO at Signufarma, explains how patient compliance programs can enhance the national healthcare system through reducing the cost of treatment as well as improving patients’ quality of life and showcases the added value of Signufarma’s business solutions to enhance the medical compliance of Mexican patients. Could you please…

Mexico Ricardo Amtmann, President at Laboratorios Sanfer, explains how they have grown their business by 100 percent throughout the last three years and showcases the added value of Sanfer to patients in Mexico and internationally by offering high quality drugs and boosting the sales of in-licensed medicines. Could you introduce yourself…

Mexico Patricia López, general manager at seca Mexico, showcases the added value of seca’s product portfolio and explains that interconnectivity should be medical devices’ path of development; generating benefits for patients, physicians and government. Could you please update our international readers on the operations of seca in Mexico? “Latin America has…

Mexico Patrick Troop, CEO at Pharma Tycsa, explains the company’s unique business approach in Mexico developing “clinical pharmacies” model to address chronic diseases treatment in the points of care and the importance of public and private partnerships to enhance the national health system. Could you please introduce to our international the…

Mexico Victor Manuel Fernández Navarro, CEO at Vicma, explains how strategically important is to have a healthy business model in the distribution industry through sustainable collection period, attractive profit margins and diversified clients’ portfolio. Additionally, he showcases the value proposition of Vicma to successfully distribute high quality medicines to remote areas…

Mexico Dr. Marco A. Martinez Rios, General Director of the National Institute of Cardiology in Mexico elaborates on the institution’s rich history in Mexico and its contributions to cardiology through research, teaching and treatment. As the general director of the National Institute of Cardiology, could you introduce yourself to our international…

Mexico Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases the added value of DCS Pharma being considered the fastest option within the industry. ChemSwiss has recently merged with Dolder.…

Mexico José Alberto Peña, managing director at Marzam Mexico, showcases the benefits that distributors can offer to the healthcare and life science sector as well as Marzam’s strategy to overcome the industry challenges in Mexico. After twenty-five years working for some of the most prestigious pharmaceutical companies you accepted in November…

Mexico Carlos Pérez Muguía, CEO at NYCE, showcases the increasing added value brought by this leading Cofepris’ authorized third party (ATP) to the healthcare industry, the future objectives of the company to enter into the biotech field, and its readiness to continue helping Cofepris in other areas to further strengthen Mexico’s…

Mexico Alan Smithers, CEO at IFA Celtics, highlights the obesity as a national healthcare challenge and explains the company’s strategy to enlarge its capabilities to cope with the increasing needs of the patients’ and physicians’ communities. Could you please introduce yourself to our international as well as the main activities and…

Mexico Salomon Rayek, CEO at Sinbiotik, explains how the company managed to adapt its business model to the industry trends and showcases the added value of Sinbiotik when offering high quality, cost-effective and fully regulated APIs manufactured locally. Could you please introduce yourself to our international audience as well as the…

Mexico This chart gives an insight into the phenomenal importance of the pharmaceutical industry to Mexico, in terms of both monetary value and employment created. Public, private, and out of pocket healthcare coverage in Mexico. The growth of the Mexican pharma industry by patented, generic and OTC segments. API Manufacturing compared…